MorphoSys Fills Out Pipeline With Xencor Deal
This article was originally published in The Pink Sheet Daily
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.
You may also be interested in...
German biotech Morphosys has filed an F-1 registration statement with the US Securities & Exchange Commission to list the ADSs on the Nasdaq Global Market to raise its profile among US investors and raise up to $150m. Funds will primarily be used to support the company’s ambitions to commercialize MOR208 in the US.
MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.
MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.